Disease · MONDO_0006769

gastroparesis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastroparesis. Diseases, record MONDO_0006769. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006769

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastroparesis; Open Targets
Open Targets ID: MONDO_0006769; Open Targets
Other names: Gastroparesis syndrome (disorder) [Ambiguous], gastric atonia (disorder), gastroparalysis, gastroparesis (disease), gastroparesis syndrome; Open Targets
Disease Ontology: DOID:11914; Disease Ontology
MeSH: D018589; MeSH
Highest stage of its drugs: Approval, for 1 of its 44 drugs, from DailyMed; Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METOCLOPRAMIDE HYDROCHLORIDE	CHEMBL1200940	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DOMPERIDONE	CHEMBL219916	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
METOCLOPRAMIDE	CHEMBL86	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
RELAMORELIN	CHEMBL4297525	Small molecule	Phase 3	ClinicalTrials.gov and TTD	6	5	4	Drugs and targets
TRADIPITANT	CHEMBL3544984	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
NORTRIPTYLINE HYDROCHLORIDE	CHEMBL1201156	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PRUCALOPRIDE	CHEMBL117287	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEUDOMPERIDONE	CHEMBL4594380	Small molecule	Phase 2	ClinicalTrials.gov	4	3	3	Drugs and targets
CAMICINAL	CHEMBL489095	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
TZP-102	CHEMBL4594424	Protein	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets33

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR4	5-hydroxytryptamine receptor 4	7	Serotonin 4 (5-HT4) receptor agonist	Approval	https://conductscience.org/library/genes/3360	Drugs and targets
DRD2	D(2) dopamine receptor	5	D2-like dopamine receptor antagonist; Dopamine D2 receptor antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR3A	5-hydroxytryptamine receptor 3A	4	Serotonin 3 (5-HT3) receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist	Approval	https://conductscience.org/library/genes/3359	Drugs and targets
GHSR	Growth hormone secretagogue receptor type 1	3	Ghrelin receptor agonist	Phase 3	https://conductscience.org/library/genes/2693	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Unknown	https://conductscience.org/library/genes/6616	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
DRD3	D(3) dopamine receptor	2	D2-like dopamine receptor antagonist; Dopamine D3 receptor antagonist	Phase 2	https://conductscience.org/library/genes/1814	Drugs and targets
MLNR	Motilin receptor	2	Motilin receptor agonist	Phase 2	https://conductscience.org/library/genes/2862	Drugs and targets
ACHE	Acetylcholinesterase	1	Acetylcholinesterase inhibitor	Phase 2	https://conductscience.org/library/genes/43	Drugs and targets
ATP4A	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Unknown	https://conductscience.org/library/genes/495	Drugs and targets

1 to 10 of 33

See all 33 targets

Trials66

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03420781	A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03	Phase 3	467	2021-12-22	Gastroparesis, Diabetes Mellitus	RELAMORELIN	Its record names the disease	ClinicalTrials.gov
NCT03285308	A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01	Phase 3	336	2021-07-29	Gastroparesis, Diabetes Mellitus	RELAMORELIN	Its record names the disease	ClinicalTrials.gov
NCT03426345	Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02	Phase 3	311	2021-08-06	Gastroparesis, Diabetes Mellitus	RELAMORELIN	Its record names the disease	ClinicalTrials.gov
NCT00845858	Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis	Phase 2	287	2014-06-17	Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus, Delayed Gastric Emptying	METOCLOPRAMIDE	Its record names the disease	ClinicalTrials.gov
NCT03544229	A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis	Phase 2	242	2022-11-16	Diabetic Gastroparesis, Idiopathic Gastroparesis	TRAZPIROBEN	Its record names the disease	ClinicalTrials.gov
NCT02025725	Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis	Phase 3	205	2020-02-11	Diabetic Gastroparesis	METOCLOPRAMIDE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04303195	A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis	Phase 2	161	2025-08-28	Diabetic Gastroparesis, Idiopathic Gastroparesis	METOPIMAZINE	Its record names the disease	ClinicalTrials.gov
NCT00765895	Nortriptyline for Idiopathic Gastroparesis	Phase 3	130	2015-04-16	Idiopathic Gastroparesis	NORTRIPTYLINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02210000	A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis	Phase 2	114	2017-11-01	Gastroparesis	CAMICINAL	Its record names the disease	ClinicalTrials.gov
NCT02170870	Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus	Phase 2	104	2019-04-23	Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms	AVEXITIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 66

See all 66 trials

Comparisons in its trials29

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Relamorelin 10 μg vs Placebo: deaths from any cause	0 of 169	0 of 167	336	NCT03285308	Trial comparisons
Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Meaningful Trends for Vital Signs	0 of 163	0 of 163	326	NCT03285308	Trial comparisons
Relamorelin 10 μg vs Placebo: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)	70 of 163	68 of 163	326	NCT03285308	Trial comparisons
Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results	3 of 163	4 of 163	326	NCT03285308	Trial comparisons
Relamorelin 10 μg vs Placebo: serious adverse events	16 of 163	15 of 163	326	NCT03285308	Trial comparisons
Relamorelin 10 μg vs Placebo: deaths from any cause	0 of 156	0 of 155	311	NCT03426345	Trial comparisons
Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Meaningful Trends for Vital Signs	0 of 155	0 of 152	307	NCT03426345	Trial comparisons
Relamorelin 10 μg vs Placebo: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAE)	86 of 155	75 of 152	307	NCT03426345	Trial comparisons
Relamorelin 10 μg vs Placebo: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Results	2 of 155	1 of 152	307	NCT03426345	Trial comparisons
Relamorelin 10 μg vs Placebo: serious adverse events	8 of 155	6 of 152	307	NCT03426345	Trial comparisons

1 to 10 of 29

See all 29 comparisons in its trials

Papers from its trials27

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38237696	RESULT	1	PubMed
18070232	RESULT	1	PubMed
17488253	RESULT	1	PubMed
16997628	RESULT	1	PubMed
16553582	RESULT	1	PubMed
10332535	RESULT	1	PubMed
9177513	RESULT	1	PubMed
40367443	DERIVED	1	PubMed
40148033	DERIVED	1	PubMed
37924856	DERIVED	1	PubMed

1 to 10 of 27

See all 27 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006769

GET https://conductscience.org/api/diseases/v1/MONDO_0006769/drugs?page=2

API reference For AI assistants